IWMY yields 57.87% · JNJ yields 2.13%● Live data
📍 IWMY pulled ahead of the other in Year 1
Combined, IWMY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IWMY + JNJ for your $10,000?
IWMY is actively managed to seek potential daily income on the price, and monthly distributions by utilizing options strategies. The fund implements two strategies: The first seeks to provide daily income by selling put options either at-the-money or up to 5% in-the-money, expiring the next trading day. The option positions become profitable if the Russell 2000 Index increases in value. The second strategy involves selling in-the-money put options to attempt a minimum daily income of 0.25% to seek monthly distributions. If this is determined to not be achievable, the fund will sell options that are priced at the current market value to maximize income. Even during periods of adverse market conditions, the fund will not seek defensive positions and it will not directly or fully participate in the gains of the index. The funds risk and return potential will fluctuate daily. A significant portion of the portfolio will be held in short-term US Treasury securities, which will serve as collateral for the short put option positions.
Full IWMY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.